Radiologists Urge Cigna to Rescind Coverage Restriction for Key Imaging Procedure

Why It Matters

The decision directly affects patient access to a proven, non‑opioid pain therapy and signals how insurers evaluate emerging interventional technologies.

Key Takeaways

• Cigna deems implantable PNS medically unnecessary
• SIR cites randomized trials supporting PNS efficacy
• Policy 0539 set to review March 15
• Over 100,000 physicians oppose restriction
• Restriction could limit opioid‑sparing pain treatments

Pulse Analysis

Peripheral nerve stimulation (PNS) has moved from experimental status to a mainstream, minimally invasive option for chronic pain management. FDA‑cleared devices deliver targeted electrical impulses through leads placed adjacent to peripheral nerves, reducing nociceptive signaling without systemic medication. Multiple randomized controlled trials have demonstrated statistically significant reductions in pain scores, decreased disability, and lower opioid consumption, positioning PNS as a cost‑effective alternative in the pain‑care algorithm. Radiology societies argue that the procedure’s safety profile—characterized by low infection rates and outpatient execution—meets the evidentiary threshold for medical necessity.

Cigna’s policy 0539, issued in May 2023, classifies implantable PNS and peripheral nerve field stimulation as investigational, effectively barring reimbursement for most providers. The insurer cites concerns about off‑label applications such as headache or trigeminal neuralgia treatment, despite clinical guidelines endorsing PNS for selected chronic back and limb pain. In response, the Society of Interventional Radiology, joined by the American College of Radiology and other specialty groups, has mobilized a coordinated lobbying effort, submitting letters to Cigna and Medicare contractors to overturn the restriction before its March 15 review.

The dispute highlights a broader tension between payers seeking to contain costs and clinicians advocating for evidence‑based, opioid‑sparing therapies. If Cigna maintains its stance, patients may face delayed access to a modality that can reduce reliance on high‑dose opioids, potentially increasing long‑term healthcare expenditures. Conversely, a policy reversal could set a precedent for faster adoption of emerging interventional technologies, encouraging manufacturers to invest in further research and expanding the market for outpatient pain solutions. Stakeholders will watch the outcome closely as it may reshape coverage criteria across the private‑insurance landscape.